Danaher Co. (NYSE:DHR) Shares Sold by Koa Wealth Management LLC

Koa Wealth Management LLC decreased its position in Danaher Co. (NYSE:DHR) by 1.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,309 shares of the conglomerate’s stock after selling 220 shares during the period. Danaher comprises 3.1% of Koa Wealth Management LLC’s investment portfolio, making the stock its 8th biggest position. Koa Wealth Management LLC’s holdings in Danaher were worth $3,744,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Decker Retirement Planning Inc. purchased a new position in Danaher in the fourth quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Danaher in the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher during the third quarter worth about $40,000. FSA Wealth Management LLC purchased a new stake in Danaher in the 3rd quarter valued at $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in Danaher during the 3rd quarter worth approximately $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $277.00 target price (down previously from $299.00) on shares of Danaher in a report on Thursday. Wells Fargo & Company reduced their target price on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday. KeyCorp boosted their price objective on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Scotiabank began coverage on Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target for the company. Finally, Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a research report on Thursday, October 31st. Six investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $278.00.

Danaher Stock Performance

Shares of DHR stock opened at $223.16 on Friday. Danaher Co. has a 12-month low of $221.34 and a 12-month high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market capitalization of $161.19 billion, a price-to-earnings ratio of 42.59, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The business has a 50 day simple moving average of $235.89 and a 200 day simple moving average of $253.45.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same quarter last year, the company posted $2.09 earnings per share. On average, equities research analysts anticipate that Danaher Co. will post 7.5 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.48%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.